Biopharma firm Clene reports Q3 net loss of $8.8 mln
Biopharma firm Clene reported a Q3 net loss of $8.8 million, up from $8.0 million last year. The company has $7.9 million in cash, extending its runway into Q2 2026. Clene plans to submit an NDA for CNM-Au8 in Q1 2026 and expects to dose the first patient in a Phase 3 ALS trial in H1 2026. Research and development expenses decreased to $3.5 million from $4.5 million. Analysts rate the stock as a "buy," with a 12-month price target of $30.00, 68.6% above the current price.
)
Overview
- Clene reports Q3 net loss of $8.8 mln, increased from $8.0 mln last year
- Cash and cash equivalents total $7.9 mln, runway extended into Q2 2026
- Company plans NDA submission for CNM-Au8 in Q1 2026 under accelerated approval
Outlook
- Clene plans to submit NDA for ALS treatment in Q1 2026
- Company expects first patient dosed in Phase 3 ALS trial in H1 2026
- Clene extends cash runway into Q2 2026
Result Drivers
- Research and development expenses were $3.5 million for the quarter ended September 30, 2025, compared to $4.5 million for the same period in 2024
Key Details
Metric Beat/Mis Actual Consensu
s s
Estimate
Q3 Net -$8.78
Income mln
Q3 Basic -$0.85
EPS
Q3 -$5.65
Income mln
From
Operatio
ns
Q3 $5.66
Operatin mln
g
Expenses
Q3 -$8.78
Pretax mln
Profit
Analyst Coverage
- The current average analyst rating on the shares is “buy” and the breakdown of recommendations is 7 “strong buy” or “buy”, no “hold” and no “sell” or “strong sell”
- The average consensus recommendation for the biotechnology & medical research peer group is “buy”
- Wall Street’s median 12-month price target for Clene Inc is $30.00, about 68.6% above its November 12 closing price of $9.41
Press Release: For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact . (This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)
